Patent Grant
11413455
The present invention relates generally to treatment and prevention of Alzheimer's diseases, and specifically to electrical techniques for treating and preventing Alzheimer's disease.
Alzheimer's disease is a chronic neurodegenerative disease that causes dementia. Accumulation of amyloid beta in the brain is widely believed to contribute to the development of Alzheimer's disease.
US Patent Application Publication 2014/0324128 to Gross, which is incorporated herein by reference, describes apparatus for driving fluid between first and second anatomical sites of a subject. The apparatus comprises (1) a first electrode, configured to be coupled to the first anatomical site of the subject; (2) a second electrode, configured to be coupled to the second anatomical site of the subject; and (3) a control unit, configured to (i) detect a pressure difference between the first and second anatomical sites, and (ii) in response to the detected pressure difference, drive fluid between the first and second anatomical sites by applying a treatment voltage between the first and second electrodes. Other embodiments are also described.
PCT Publication WO 2017/006327 to Gross, which is incorporated herein by reference, describes an electrical amyloid beta-clearance system for treating a subject identified as at risk of or suffering from Alzheimer's disease. The system includes (a) midplane treatment electrodes, adapted to be disposed over a superior sagittal sinus, outside and in electrical contact with a skull of a head of the subject; and (b) lateral treatment electrodes, adapted to be disposed between 1 and 12 cm of a sagittal midplane of the skull. The system further includes control circuitry, configured to clear amyloid beta from a subarachnoid space to the superior sagittal sinus, by applying one or more treatment currents between (a) one or more of the midplane treatment electrodes and (b) one or more of the lateral treatment electrodes. Other embodiments are also described.
PCT Publication WO 2017/072769 to Fostick et al., which is incorporated herein by reference, describes a system that includes a parenchymal electrode, configured to be implanted in brain parenchyma of a subject identified as at risk of or suffering from a disease; and a cerebrospinal fluid (CSF) electrode, configured to be implanted in a CSF-filled space of a brain of the subject, the CSF-filled space selected from the group consisting of: a ventricular system and a subarachnoid space. Control circuitry is configured to drive the parenchymal electrode and the CSF electrode to clear a substance from the brain parenchyma into the CSF-filled space of the brain. Other embodiments are also described.
Some embodiments of the present invention provide a system and methods for treating Alzheimer's disease by enhancing the clearance of waste products from the brain. The system comprises central electrodes, peripheral electrodes, and control circuitry, which is electrically coupled to the electrodes. For some applications, a method for treating Alzheimer's disease comprises:
Typically, after being cleared to the subarachnoid space by the applied currents, the substance is naturally drained with cerebrospinal fluid (CSF) from the subarachnoid space to a superior sagittal sinus (through arachnoid granulations and villi).
For some applications, the peripheral electrodes comprise left peripheral electrodes and right peripheral electrodes, adapted to be disposed outside and in electrical contact with the skull, left and right of the sagittal midplane, respectively, superior to the orbitomeatal plane and inferior to the first plane. The control circuitry is configured to treat the subject by (i) applying the respective currents (a) between the one or more of the central electrodes and one or more of the left peripheral electrodes and (b) between one or more of the central electrodes and one or more of the right peripheral electrodes, and (ii) configuring the central electrodes as the cathodes, the left peripheral electrodes as anodes, and the right peripheral electrodes as anodes. For some of these applications, the control circuitry is activated to independently apply the respective currents to (a) respective pairs of the central electrodes and the left peripheral electrodes and (b) respective pairs of the central electrodes and the right peripheral electrodes.
In experiments conducted on behalf of the inventor, amyloid beta was found to be attracted to the positive electrode (anode).
There is therefore provided, in accordance with an Inventive Concept 1 of the present invention, a method including:
disposing central electrodes outside and in electrical contact with a skull of a head of a subject identified as at risk of or suffering from Alzheimer's disease, within one cm of a sagittal midplane of the skull;
disposing peripheral electrodes outside and in electrical contact with the skull, superior to an orbitomeatal plane of the skull and inferior to a first plane midway between the orbitomeatal plane and a cranial vertex of the skull, the first plane parallel to the orbitomeatal plane; and
treating the subject by clearing a substance from brain parenchyma to a subarachnoid space, the substance selected from the group consisting of: amyloid beta, tau protein, and metal ions, by activating control circuitry to:
wherein the peripheral electrodes include left peripheral electrodes and right peripheral electrodes,
wherein disposing the peripheral electrodes includes disposing the left peripheral electrodes and right peripheral electrodes outside and in electrical contact with the skull, left and right of the sagittal midplane, respectively, superior to the orbitomeatal plane and inferior to the first plane, and
wherein activating the control circuitry includes activating the control circuitry to:
a first current between a first one of the central electrodes and a first one of the left peripheral electrodes,
a second current between the first one of the central electrodes and a first one of the right peripheral electrodes,
a third current between a second one of the central electrodes and a second one of the left peripheral electrodes, and
a fourth current between the second one of the central electrodes and a second one of the right peripheral electrodes.
Inventive Concept 18. The method according to Inventive Concept 1,
wherein the peripheral electrodes are left peripheral electrodes,
wherein disposing the peripheral electrodes includes disposing the left peripheral electrodes outside and in electrical contact with the skull, left of the sagittal midplane, superior to the orbitomeatal plane and inferior to the first plane, and
wherein activating the control circuitry includes activating the control circuitry to:
There is further provided, in accordance with an Inventive Concept 33 of the present invention, an electrical substance-clearance system for treating a subject identified as at risk of or suffering from Alzheimer's disease, the system including:
central electrodes, adapted to be disposed outside and in electrical contact with a skull of a head of the subject, within one cm of a sagittal midplane of the skull;
peripheral electrodes, adapted to be disposed outside and in electrical contact with the skull, superior to an orbitomeatal plane of the skull and inferior to a first plane midway between the orbitomeatal plane and a cranial vertex of the skull, the first plane parallel to the orbitomeatal plane; and
control circuitry, configured to treat the subject by clearing a substance from brain parenchyma to a subarachnoid space, the substance selected from the group consisting of: amyloid beta, tau protein, and metal ions, by:
wherein the system further includes (a) a central lead, which is adapted to be disposed outside the skull, and (b) a peripheral lead, adapted to be disposed outside the skull, superior to the orbitomeatal plane and inferior to the first plane,
wherein the system includes at least five central electrodes that are disposed along the central lead, and
wherein the system includes at least five peripheral electrodes that are disposed along the peripheral lead.
Inventive Concept 37. The system according to Inventive Concept 33, wherein the control circuitry is configured to apply the respective currents as respective DC currents.
Inventive Concept 38. The system according to Inventive Concept 33, wherein the control circuitry is configured to limit, to maximum value, an amplitude of each of the respective currents, the maximum value 1-5 milliamps.
Inventive Concept 39. The system according to Inventive Concept 33, wherein the control circuitry is configured to apply the respective currents by applying respective voltages, each of which equals the lesser of (a) a predefined maximum voltage and (b) a voltage that results in a current having a predefined maximum amplitude.
Inventive Concept 40. The system according to Inventive Concept 39, wherein the predefined maximum voltage is 2-15 V.
Inventive Concept 41. The system according to any one of Inventive Concepts 33-40,
wherein the peripheral electrodes include left peripheral electrodes and right peripheral electrodes, adapted to be disposed outside and in electrical contact with the skull, left and right of the sagittal midplane, respectively, superior to the orbitomeatal plane and inferior to the first plane, and
wherein the control circuitry is configured to treat the subject by:
wherein the system further includes (a) a central lead, which is adapted to be disposed outside the skull, and (b) a left peripheral lead and a right peripheral lead, adapted to be disposed outside the skull, left and right of the sagittal midplane, respectively, superior to the orbitomeatal plane and inferior to the first plane,
wherein the system includes at least five central electrodes that are disposed along the central lead, and
wherein the system includes at least five left peripheral electrodes and at least five right peripheral electrodes that are disposed along the left peripheral lead and the right peripheral lead, respectively.
Inventive Concept 44. The system according to Inventive Concept 41, wherein the control circuitry is configured to apply the one or more currents between (a) the one or more of the central electrodes and (b) the one or more of the peripheral electrodes includes activating the control circuitry to apply:
a first current between a first one of the central electrodes and a first one of the left peripheral electrodes,
a second current between the first one of the central electrodes and a first one of the right peripheral electrodes,
a third current between a second one of the central electrodes and a second one of the left peripheral electrodes, and
a fourth current between the second one of the central electrodes and a second one of the right peripheral electrodes.
Inventive Concept 45. The system according to any one of Inventive Concepts 33-40,
wherein the peripheral electrodes are left peripheral electrodes, which are adapted to be disposed outside and in electrical contact with the skull, left of the sagittal midplane, superior to the orbitomeatal plane and inferior to the first plane, and
wherein the control circuitry is configured to treat the subject by:
The present invention will be more fully understood from the following detailed description of embodiments thereof, taken together with the drawings, in which:
For some applications, peripheral electrodes 32 comprise:
For clarity of illustration, right peripheral electrodes 32B are not shown in
For some applications, the number of each type of electrode is determined based on the size of head 44 of the subject. System 20 further comprises control circuitry 34, which is electrically coupled to the electrodes.
Reference is still made to
Reference is still further made to
For some applications, a method for treating Alzheimer's disease comprises:
Typically, the substance is amyloid beta, tau protein, and/or metal ions.
Typically, after being cleared to subarachnoid space 50 by the applied currents, the substance is naturally drained with cerebrospinal fluid (CSF) from subarachnoid space 50 to a superior sagittal sinus 40 (through arachnoid granulations and villi). (It is noted that the natural flow of CSF within subarachnoid space 50 toward superior sagittal sinus 40, schematically illustrated in
Typically, central electrodes 30 are disposed over or near a superior sagittal sinus 40. As used in the present application, including in the claims and Inventive Concepts, “over the superior sagittal sinus” means aligned with the superior sagittal sinus at a location more superficial than the superior sagittal sinus, i.e., at a greater distance from a center of the head.
As used in the present application, including the claims and Inventive Concepts, “treating” includes both treating a subject already diagnosed with a disease, as well as preventing the development of the disease in a subject not diagnosed with the disease and/or asymptomatic for the disease (for example, the disease may be Alzheimer's disease, cerebral amyloid angiopathy (CAA), or hydrocephalus, such as normal pressure hydrocephalus). In the case of normal pressure hydrocephalus, the electrical treatment described herein may help increase flow of cerebrospinal fluid (CSF) through clogged arachnoid granulations, such as because of the negative charge of central electrodes 30.
For some applications:
Reference is made to
Reference is still made to
For some applications, peripheral electrodes 32 (e.g., left peripheral electrodes 32A and right peripheral electrodes 32B) are disposed superior to a third plane 29 located at a distance D4 from orbitomeatal plane 24 equal to 5%, e.g., 10%, of the distance D1 between orbitomeatal plane 24 and cranial vertex 28. Third plane 29 is parallel to orbitomeatal plane 24.
Reference is again made to
Providing peripheral electrodes 32 on a single side of skull 42 may be appropriate, for example, for personalizing therapy for a patient whose brain has amyloid plaques on only one side, or primarily only on one side. For example, the location of the amyloid plaques may be ascertained using amyloid positive emission tomography (PET), as is known in the art.
Reference is still made to
Reference is made to
Reference is still made to
Reference is still made to
Reference is still made to
For some applications, system 20 further comprises (a) a central lead 70, which is adapted to be disposed outside skull 42, and (b) a peripheral lead, adapted to be disposed outside skull 42, superior to orbitomeatal plane 24 and inferior to first plane 26. Central electrodes 30 are disposed (e.g., fixed) along central lead 70, and peripheral electrode 32 are disposed (e.g., fixed) along the peripheral leads. For some applications, system 20 comprises a left peripheral lead 72A and a right peripheral lead 72B, adapted to be disposed outside skull 42, left and right of sagittal midplane 46, respectively, superior to orbitomeatal plane 24 and inferior to first plane 26. Left and right peripheral electrodes 32A and 32B are disposed (e.g., fixed) along left and right peripheral leads 72A and 72B, respectively.
For some applications, system 20 comprises at least five central electrodes 30 that are disposed along central lead 70, and at least five peripheral electrodes 32A that are disposed along the peripheral lead. For some applications, system 20 comprises at least five central electrodes 30 that are disposed along central lead 70, and at least five left peripheral electrodes 32A and at least five right peripheral electrodes 32B that are disposed along left peripheral lead 72A and right peripheral lead 72B, respectively. As a result, the electrical field generated by the applied currents typically passes through large portions of the brain.
Reference is again made to
For some applications in which central electrodes 30 are implanted under skin 64 and disposed along central lead 70, the implantation is performed by introducing central lead 70 through an incision in skin 64, typically at a posterior site of the head, and tunneling the central lead toward an anterior site of the head, such as near the forehead. Optionally, each of central electrodes 30 is inserted through a respective incision in skin 64, and connected to central lead 70.
For some applications in which left peripheral electrodes 32A and/or right peripheral electrodes 32B are implanted under skin 64 and disposed along left and right peripheral leads 72A and 72B, respectively, the implantation is performed by introducing left and right peripheral leads 72A and 72B through respective incisions in skin 64, typically at a posterior site of the head, and tunneling the leads toward an anterior site of the head, such as near the forehead. Optionally, each of left peripheral electrodes 32A and/or right peripheral electrodes 32B is inserted through a respective incision in skin 64, and connected to their respective lead.
For some applications, the method further comprises implanting control circuitry 34 under skin of the subject, such as under skin 64 of head 44, or elsewhere in the subject's body.
Reference is made to
Although the following configuration is described with reference to
For example, control circuitry 34 may be activated to apply:
Such independent application of the currents may allow continued effective operation of system 20 even if a low resistance should develop between the electrodes of one of the pairs (e.g., because of anatomical variations).
For some applications, control circuitry 34 is activated to drive the respective currents through pairs of central electrodes 30 and right peripheral electrodes 32 such that stronger currents are driven through areas of the brain with amyloid plaques (e.g., ascertained with amyloid PET), and that weaker currents are applies elsewhere, such as for preventive treatment.
For some of these applications, in order to enable such independent application of the currents, central lead 70 comprises a plurality of conductive wires corresponding to a number of central electrodes 30, left peripheral lead 72A comprises a plurality of conductive wires corresponding to a number of left peripheral electrodes 32A, and/or right peripheral lead 72B comprises a plurality of conductive wires corresponding to a number of right peripheral electrodes 32B. Alternatively, control circuitry 34 and the electrodes implement electrical multiplexing, as is known in the art, in which case each of the leads need only comprise a single conductive wire. Alternatively, for some applications, all of central electrodes 30 are electrically coupled to one another (such as by a single conductive wire in the central lead), all of left peripheral electrodes 32A, and/or all of right peripheral electrodes 32B are electrically coupled to one other (such as by respective single conductive wires in the peripheral leads).
For some applications, control circuitry 34 is configured to set each of the respective currents to have respective amplitudes of at least 1 milliamp, no more than 5 milliamps (e.g., no more than 3 milliamps), and/or 1-5 milliamps, such as 1-3 milliamps; or at least 0.5 milliamps, such as 0.5-5 milliamps, e.g., 0.5-3 milliamps.
For some applications, control circuitry 34 is configured to set each of the respective currents to the lesser of (a) a predefined maximum current and (b) a current that results from application of a predefined maximum voltage. For some applications, the predefined maximum voltage is 2-15 V. This maximum voltage typically results in a voltage within the brain tissue of no more than 1.2 V, such as because of (a) the impedance of the interface between the electrodes and the tissue, and/or (b) the impedance of the peripheral tissues of the head, such as the skull and the skin.
For some applications, control circuitry 34 is configured to apply the respective currents as respective DC currents.
For some applications, control circuitry 34 is activated to apply the respective currents in treatment sessions, each of which has a duration of several seconds or several minutes, or continuously for longer periods (e.g., 30 minutes). Rest periods may optionally be provided between the treatment sessions, for example each of which has a duration of several seconds or several minutes. For example, control circuitry 34 may be configured to apply the respective currents during a portion of each treatment session, the portion having a duration greater than half of the total duration of the treatment session. For some applications, the respective currents are not applied for a period that is at least an hour. For some applications, control circuitry 34 is configured to apply the respective currents with a constant current (i.e., non-pulsed current) when applied.
Optionally, control circuitry 34 is activated to apply the respective currents only when the subject is sleeping, such as to inhibit any sensations that may be associated with application of the respective currents. For example, control circuitry 34 may be activated to use one or more of the electrodes as EEG electrodes to detect sleep. For some applications, power for activating and/or charging control circuitry 34 is transmitted from a wireless energy transmitter in a hat or from a wireless energy transmitter in, under, or above a mattress. For some applications, control circuitry 34 is activated to apply the respective currents according to a pre-selected schedule, such as a duty cycle, such as for a few hours per day. For example, control circuitry 34 may be configured to be controlled and/or powered by an extracorporeal control circuitry, such as a control circuitry comprising a wireless transmitter, disposed in and/or in the vicinity of the subject's bed. For some applications, one or more rest periods during which the respective currents are not applied are provided in the pre-selected schedule.
For some applications, system 20 comprises a housing, which contains control circuitry 34. For some applications, the housing is implantable, such as subcutaneously; for example, the housing may be similar to conventional pacemaker housings (“cans”). For some applications, the housing comprises first, second, and third lead interfaces, for electrical and mechanical coupling with central lead 70 and left and right peripheral leads 72A and 72B. For example, the first, the second, and the third lead interfaces may comprise first, second, and third ports, into which corresponding connectors of the leads are inserted. Alternatively, the leads may have hardwired connections with the lead interfaces. The first, the second, and the third lead interfaces are also electrically coupled with control circuitry 34.
Typically, the lead interfaces are physically arranged such that the second lead interface is between the first and the third lead interfaces on the housing. Typically, control circuitry 34 is configured to apply the respective currents through the second lead interface to central lead 70 such that central electrodes 30 are cathodes, and to apply the respective currents through the first and the third lead interfaces such that peripheral electrodes 32 (e.g., left and right peripheral electrodes 32A and 32B) are anodes.
Alternatively, for some applications, the housing comprises only two lead interfaces, and the left and the right peripheral leads are electrically coupled to each other so as define a single, joint connector, which is couplable to one of the lead interfaces of the housing.
Reference is made to
For some of these applications, any of these single electrodes comprises an elongate electrode having a length of at least 10 cm, no more than 40 cm (e.g., no more than 30 cm), and/or 10-40 cm (e.g., 10-30 cm); for example, the elongate electrode may comprise an electrically-non-insulated wire.
Although control circuitry 34 has generally been described hereinabove as being configured to configure central electrodes 30 as cathodes and peripheral electrodes 32 (e.g., left peripheral electrodes 32A and right peripheral electrodes 32B) as anodes, control circuitry 34 may alternatively be configured to configure electrodes 30 as anodes and peripheral electrodes 32 (e.g., left peripheral electrodes 32A and right peripheral electrodes 32B) as cathodes. This electrical polarity treats the subject by clearing the substance (e.g., amyloid beta, tau protein, and/or metal ions) from brain parenchyma 66 to superior sagittal sinus 40, typically via arachnoid granulations and/or villi.
In an embodiment, techniques and apparatus described in one or more of the following applications, which are assigned to the assignee of the present application and are incorporated herein by reference, are combined with techniques and apparatus described herein:
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4044774 | Corbin et al. | Aug 1977 | A |
| 4503863 | Katims | Mar 1985 | A |
| 4602638 | Adams | Jul 1986 | A |
| 4738250 | Fulkerson et al. | Apr 1988 | A |
| 5088977 | Sibalis | Feb 1992 | A |
| 5121754 | Mullett | Jun 1992 | A |
| 5433739 | Sluijter et al. | Jul 1995 | A |
| 5529574 | Frackelton | Jun 1996 | A |
| 5792100 | Shantha | Aug 1998 | A |
| 5911223 | Weaver et al. | Jun 1999 | A |
| 5938690 | Law et al. | Aug 1999 | A |
| 6041252 | Walker et al. | Mar 2000 | A |
| 6146380 | Racz et al. | Nov 2000 | A |
| 6161047 | King et al. | Dec 2000 | A |
| 6360750 | Gerber et al. | Mar 2002 | B1 |
| 6567702 | Nekhendzy et al. | May 2003 | B1 |
| 6591138 | Fischell et al. | Jul 2003 | B1 |
| 6602248 | Sharps et al. | Aug 2003 | B1 |
| 6620155 | Underwood et al. | Sep 2003 | B2 |
| 6941172 | Nachum | Sep 2005 | B2 |
| 6997941 | Sharkey et al. | Feb 2006 | B2 |
| 7013177 | Whitehurst et al. | Mar 2006 | B1 |
| 7120489 | Shalev et al. | Oct 2006 | B2 |
| 7155287 | Gavronsky | Dec 2006 | B2 |
| 7217351 | Krumme | May 2007 | B2 |
| 7223227 | Pflueger | May 2007 | B2 |
| 7270659 | Ricart et al. | Sep 2007 | B2 |
| 7317947 | Wahlstrand et al. | Jan 2008 | B2 |
| 7398121 | Matsumura et al. | Jul 2008 | B2 |
| 7509171 | DiMauro | Mar 2009 | B2 |
| 7640062 | Shalev | Dec 2009 | B2 |
| 7818063 | Wallace et al. | Oct 2010 | B2 |
| 7831306 | Finch et al. | Nov 2010 | B2 |
| 7860569 | Solberg et al. | Dec 2010 | B2 |
| 8060207 | Wallace et al. | Nov 2011 | B2 |
| 8190248 | Besio et al. | May 2012 | B2 |
| 8353853 | Kyle et al. | Jan 2013 | B1 |
| 8457761 | Wariar | Jun 2013 | B2 |
| 8577469 | Gross | Nov 2013 | B2 |
| 8676348 | Gross | Mar 2014 | B2 |
| 8731674 | Wallace et al. | May 2014 | B2 |
| 9616221 | Gross | Apr 2017 | B2 |
| 9724513 | Lane et al. | Aug 2017 | B2 |
| 9724515 | Fostick et al. | Aug 2017 | B2 |
| 9731122 | Gross | Aug 2017 | B2 |
| 10173063 | Fostick et al. | Jan 2019 | B2 |
| 10398884 | Lad et al. | Sep 2019 | B2 |
| 10569086 | Fostick et al. | Feb 2020 | B2 |
| 10881858 | Gross | Jan 2021 | B1 |
| 10898716 | Fostick et al. | Jan 2021 | B2 |
| 20020151948 | King et al. | Oct 2002 | A1 |
| 20020183683 | Lerner | Dec 2002 | A1 |
| 20030130707 | Gan et al. | Jul 2003 | A1 |
| 20030158589 | Katsnelson | Aug 2003 | A1 |
| 20030216792 | Levin et al. | Nov 2003 | A1 |
| 20030225331 | Diederich et al. | Dec 2003 | A1 |
| 20040002746 | Ryan et al. | Jan 2004 | A1 |
| 20040019381 | Pflueger | Jan 2004 | A1 |
| 20040049180 | Sharps et al. | Mar 2004 | A1 |
| 20040116977 | Finch et al. | Jun 2004 | A1 |
| 20040210209 | Yeung et al. | Oct 2004 | A1 |
| 20050010205 | Hovda et al. | Jan 2005 | A1 |
| 20050021104 | DiLorenzo | Jan 2005 | A1 |
| 20050119650 | Sanders et al. | Jun 2005 | A1 |
| 20050137646 | Wallace et al. | Jun 2005 | A1 |
| 20050137647 | Wallace et al. | Jun 2005 | A1 |
| 20050159790 | Shalev | Jul 2005 | A1 |
| 20050187589 | Wallace et al. | Aug 2005 | A1 |
| 20050203599 | Garabedian et al. | Sep 2005 | A1 |
| 20050203600 | Wallace et al. | Sep 2005 | A1 |
| 20050203602 | Wallace et al. | Sep 2005 | A1 |
| 20050222647 | Wahlstrand et al. | Oct 2005 | A1 |
| 20050277996 | Podhajsky et al. | Dec 2005 | A1 |
| 20060030895 | Simon et al. | Feb 2006 | A1 |
| 20060106430 | Fowler et al. | May 2006 | A1 |
| 20060224223 | Podhajsky et al. | Oct 2006 | A1 |
| 20060293723 | Whitehurst et al. | Dec 2006 | A1 |
| 20070000784 | Paul et al. | Jan 2007 | A1 |
| 20070073402 | Vresilovic et al. | Mar 2007 | A1 |
| 20070162086 | Dilorenzo | Jul 2007 | A1 |
| 20070213700 | Davison et al. | Sep 2007 | A1 |
| 20070255338 | Wahlstrand | Nov 2007 | A1 |
| 20080009927 | Vilims | Jan 2008 | A1 |
| 20080119907 | Stahmann | May 2008 | A1 |
| 20080260542 | Nishikawa et al. | Oct 2008 | A1 |
| 20090062885 | Brighton et al. | Mar 2009 | A1 |
| 20090112278 | Wingeier et al. | Apr 2009 | A1 |
| 20090125080 | Montgomery | May 2009 | A1 |
| 20090126813 | Yanagisawa et al. | May 2009 | A1 |
| 20090131850 | Geiger | May 2009 | A1 |
| 20090312816 | Gross | Dec 2009 | A1 |
| 20100217369 | Gross | Aug 2010 | A1 |
| 20100324441 | Hargrove et al. | Dec 2010 | A1 |
| 20110046540 | Alterman et al. | Feb 2011 | A1 |
| 20110054518 | Carbunaru et al. | Mar 2011 | A1 |
| 20110160638 | Mauge et al. | Jun 2011 | A1 |
| 20110160797 | Makous et al. | Jun 2011 | A1 |
| 20120053659 | Molnar et al. | Mar 2012 | A1 |
| 20120191159 | Willeford | Jul 2012 | A1 |
| 20120203307 | Schroeppel et al. | Aug 2012 | A1 |
| 20130066392 | Simon et al. | Mar 2013 | A1 |
| 20130102952 | Gross | Apr 2013 | A1 |
| 20130166006 | Williams | Jun 2013 | A1 |
| 20130289385 | Lozano et al. | Oct 2013 | A1 |
| 20140058189 | Stubbeman | Feb 2014 | A1 |
| 20140088672 | Bedenbaugh | Mar 2014 | A1 |
| 20140207224 | Simon | Jul 2014 | A1 |
| 20140257168 | Gill | Sep 2014 | A1 |
| 20140324128 | Gross | Oct 2014 | A1 |
| 20150011927 | Hua | Jan 2015 | A1 |
| 20150038948 | Ludvig | Feb 2015 | A1 |
| 20150119898 | Desalles et al. | Apr 2015 | A1 |
| 20160144164 | Sedighiani | May 2016 | A1 |
| 20160331970 | Lozano | Nov 2016 | A1 |
| 20170007823 | Gross | Jan 2017 | A1 |
| 20170056642 | Moffitt et al. | Mar 2017 | A1 |
| 20170120053 | Fostick et al. | May 2017 | A1 |
| 20170182317 | Gross et al. | Jun 2017 | A1 |
| 20170296821 | Fostick et al. | Oct 2017 | A1 |
| 20180071523 | Gross et al. | Mar 2018 | A1 |
| 20180193646 | Fostick | Jul 2018 | A1 |
| 20180318575 | Gross et al. | Nov 2018 | A1 |
| 20190076653 | Fostick | Mar 2019 | A1 |
| 20190282807 | Tendler | Sep 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 2004-321242 | Nov 2004 | JP |
| 2005011805 | Feb 2005 | JP |
| 2007-501067 | Jan 2007 | JP |
| 9405369 | Mar 1994 | WO |
| 0152931 | Jul 2001 | WO |
| 0185027 | Nov 2001 | WO |
| 2001085094 | Nov 2001 | WO |
| 2006090397 | Aug 2006 | WO |
| 2008007369 | Jan 2008 | WO |
| 2017006327 | Jan 2017 | WO |
| 2017072769 | May 2017 | WO |
| 2017115351 | Jul 2017 | WO |
| 2018051338 | Mar 2018 | WO |
| Entry |
|---|
| Karran September E et201 al., 1 “The Amyloid cascade hypothesis for AD,” Nature Reviews Drug Discovery, vol. 10; 698-712. |
| De La Torre JC, “Vascular Basis of Alzheimer's Pathogensis,” Ann NY Acad Sci. 977:196-215 (Nov. 2002). |
| Weller RO et al, “Perivascular Drainage of Amyloid-b Peptides from the Brain and Its Failure in Cerebral Amyloid Angiopathy and Alzheimer's Disease,” Brain Pathology 18 (Apr. 2008) 253-266. |
| Brief PubMed search for metal ions in Alzheimers. |
| An Office Action dated Sep. 27, 2016, which issued during the prosecution of U.S. Appl. No. 14/926,705. |
| An International Search Report and a Written Opinion both dated Aug. 7, 2008, which issued during the prosecution of Applicant's PCT/IL2007/000865. |
| An Office Action dated Mar. 29, 2013, which issued during the prosecution of U.S. Appl. No. 12/373,306. |
| An Office Action dated Oct. 31, 2011, which issued during the prosecution of U.S. Appl. No. 12/373,306. |
| An Office Action dated Oct. 1, 2012, which issued during the prosecution of U.S. Appl. No. 12/373,306. |
| Notice of Allowance dated Jul. 24, 2013, which issued during the prosecution of U.S. Appl. No. 12/373,306. |
| An Office Action dated Apr. 11, 2013, which issued during the prosecution of U.S. Appl. No. 13/663,757. |
| Notice of Allowance dated Oct. 28, 2013, which issued during the prosecution of U.S. Appl. No. 13/663,757. |
| Elixmann IM et al., “In-vitro evaluation of a drainage catheter with integrated bioimpedance electrodes to determine ventricular size,” Biomed Tech 2013; 58 (Suppl. 1) Sep. 2013 (2 pages total). |
| An Office Action dated Aug. 31, 2015, which issued during the prosecution of U.S. Appl. No. 13/872,794. |
| An Applicant Initiated Interview Summary dated Dec. 14, 2015, which issued during the prosecution of U.S. Appl. No. 13/872,794. |
| An Office Action dated Feb. 3, 2016, which issued during the prosecution of U.S. Appl. No. 13/872,794. |
| Notice of Allowance dated Dec. 9, 2016, which issued during the prosecution of U.S. Appl. No. 14/794,739. |
| An Applicant Initiated Interview Summary dated Feb. 25, 2016, which issued during the prosecution of U.S. Appl. No. 13/872,794. |
| An Office Action dated Jun. 15, 2016, which issued during the prosecution of U.S. Appl. No. 13/872,794. |
| An International Search Report and a Written Opinion both dated Oct. 20, 2016, which issued during the prosecution of Applicant's PCT/IL2016/050728. |
| An Office Action dated Sep. 21, 2016, which issued during the prosecution of U.S. Appl. No. 14/794,739. |
| An International Search Report and a Written Opinion both dated Jan. 26, 2017, which issued during the prosecution of Applicant's PCT/IL2016/051161. |
| Notice of Allowance dated Jul. 14, 2017, which issued during the prosecution of U.S. Appl. No. 13/872,794. |
| An Office Action dated May 26, 2017, which issued during the prosecution of U.S. Appl. No. 15/453,290. |
| An International Preliminary Report on Patentability dated Apr. 7, 2009, which issued during the prosecution of Applicant's PCT/IL2007/000865. |
| Loutzenhiser, “Membrane Potential measurements in renal afferent and efferent arterioles: actions of Angiotensin II”, AJP—Renal Physiol Aug. 1, 1997 vol. 273 No. 2 F307-F314. |
| U.S. Appl. No. 60/830,717, filed Jul. 12, 2006. |
| Dao-Sheng Liu et al., “Activation of Na+ and K+ Pumping Modes of (Na,K)-ATPase by an Oscillating Electric Field,” the Journal of Biological Chemistry, vol. 265. No. 13, May 5, 1990. (pp. 7260-7267). |
| Robert F. Service.. “Electric fields deliver drugs into tumors.” http://news.sciencemaa.ora. Feb. 4, 2015. (5 Pages Total). |
| Vernengo J, “Injectable Bioadhesive Hydrogels for Nucleus Pulposus Replacement and Repair of the Damaged Intervertebral Disc: A Thesis,” Drexel University (Jan. 2007). |
| Urban JPG et al., “The nucleus of the intervertebral disc from development to degeneration,” American Zoologist 40(1): 53-61 (2000). |
| Cheung KMC et al., “Intervertebral disc regeneration by use of autologous mesenchymal stem cells, an experimental model in rabbits,” Abstract from the SRS 2004 Annual Meeting. |
| Freemont TJ et al., “Degeneration of intervertebral discs: current understanding of cellular and molecular events, and implications for novel therapies,” Expert Reviews in Molecular Biology, Mar. 29, 2001 (Cambridge University Press). |
| An Office Action dated Sep. 12, 2011, which issued during the prosecution of U.S. Appl. No. 12/373,306. |
| An Office Action dated Jul. 24, 2017, which issued during the prosecution of U.S. Appl. No. 14/982,187. |
| An International Search Report and a Written Opinion both dated Mar. 10, 2017, which issued during the prosecution of Applicant's PCT/IL2016/051363. |
| An Office Action dated Apr. 25, 2018, which issued during the prosecution of U.S. Appl. No. 15/637,330. |
| U.S. Appl. No. 62/444,939, filed Jan. 11, 2017. |
| An Office Action dated Nov. 29, 2019, which issued during the prosecution of U.S. Appl. No. 15/969,411. |
| Sawyer, P N et al. “Measurement of streaming potentials of mammalian blood vessels, aorta and vena cava, in vivo.” Biophysical journal vol. 6,5 (1966): 641-51. doi:10.1016/50006-3495(66)86683-3, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1368020/, viewed on Jul. 22, 2019. |
| An Office Action dated Jul. 29, 2019, which issued during the prosecution of U.S. Appl. No. 15/618,325. |
| An International Search Report and a Written Opinion both dated May 23, 2019, which issued during the prosecution of Applicant's PCT/IL2019/050284. |
| An Office Action dated Jul. 10, 2019, which issued during the prosecution of U.S. Appl. No. 15/864,065. |
| Notice of Allowance dated Oct. 17, 2019, which issued during the prosecution of U.S. Appl. No. 15/864,065. |
| An Office Action dated Mar. 25, 2019, which issued during the prosecution of U.S. Appl. No. 15/742,245. |
| Austin SA et al., “Mechanisms of microglial activation by amyloid precursor protein and its proteolytic fragments ”In Lane TE et al. (eds.), Central nervous system diseases and inflammation. Springer US, New York, pp. 13-32 (2008). |
| Farfara D et al., “γ-Secretase component presenilin is important for microglia β-amyloid clearance,” Ann Neurol. Jan. 2011;69(1):170-80. |
| Kearns KR et al., “Macrophage response to electrical stimulation,” in 2015 41st Annual Northeast Biomedical Engineering Conference (NEBEC), Apr. 2015. |
| Nagele RG et al., “Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease” (Abstract only), Neurobiol Aging. May-Jun. 2004;25(5):663-74. |
| “The role of glial cells in amyloid-beta clearance,” Abstract, Vumc (Amsterdam, the Netherlands) Feb. 20, 2016. |
| Iaccarino HF et al., “Gamma frequency entrainment attenuates amyloid load and modifies microglia,” Nature, 540:230-251, Dec. 2016. |
| Devlin H, “Strobe lighting provides a flicker of hope in the fight against Alzheimer's,” The Guardian, Dec. 7, 2016. |
| An Office Action dated Mar. 6, 2020, which issued during the prosecution of U.S. Appl. No. 15/618,325. |
| An Office Action together with the English translation dated Aug. 19, 2020, which issued during the prosecution of Japanese Patent Application No. 2018-521586. |
| An Office Action dated Mar. 30, 2020, which issued during the prosecution of U.S. Appl. No. 16/574,772. |
| An Office Action dated Nov. 20, 2020, which issued during the prosecution of U.S. Appl. No. 16/353,407. |
| An International Search Report and a Written Opinion both dated Dec. 20, 2020, which issued during the prosecution of Applicant's PCT/IL2020/051022. |
| An Office Action dated May 25, 2021, which issued during the prosecution of U.S. Appl. No. 16/353,407. |
| An Office Action dated Nov. 4, 2021, which issued during the prosecution of U.S. Appl. No. 16/713,660. |
| Final Office Action issued in U.S. Appl. No. 16/353,407, dated May 25, 2021. |
| Non-Final Office Action issued in U.S. Appl. No. 17/402,911, dated Oct. 28, 2021. |
